Areas announces partnership for new TB vaccine candidates

Non-profit tuberculosis vaccine developer Aeras and the China National Biotec Group recently announced that they have reached an agreement to collaborate on new TB vaccine candidates.

The agreement signals a commitment to engage China in the fight against one of the world’s deadliest infectious diseases.

"CNBG has a great deal of expertise and energy to invest in this partnership,” CNBG President Xiaoming Yang said. “Not only is TB a public health crisis of the developing world, it is also a priority health issue here in China. We look forward to working with our counterparts at Aeras to develop new TB vaccines that will help stop tuberculosis in all corners of the world,” he continued.

A group of leading Chinese research institutes operating under CNBG plans to work with Aeras to create a strategy focused on the joint development, manufacturing and distribution of affordable TB vaccines for use around the world. The agreement covers all aspects of a new drug’s creation from discovery to clinical research and manufacturing.

“The synergy created by bringing together our scientific and manufacturing expertise could have a substantial impact on efforts to advance innovative candidates in TB vaccine development,” Aeras President and CEO Jim Connolly said.